Key Points
- Insider sale: Esther Rajavelu sold 18,442 shares on Feb. 2 at an average price of $2.20 for $40,572, reducing her stake to 1,100,008 shares (a 1.65% decrease); she also sold 40,270 shares on Nov. 7 at $2.37.
- Stock & results: SPRO traded up 3.0% to $2.37 (market cap ~ $133.5M; 52-week range $0.51–$3.22), and remains unprofitable—Q3 EPS was -$0.13 (beat estimates) while revenue missed at $5.44M vs. $12M expected.
- Market sentiment: Analyst views are mixed (ratings from Buy to Sell, average rating "Reduce") and institutional/hedge fund ownership stands at about 25.6%.
Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) insider Esther Rajavelu sold 18,442 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $2.20, for a total value of $40,572.40. Following the transaction, the insider owned 1,100,008 shares of the company's stock, valued at approximately $2,420,017.60. This trade represents a 1.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Esther Rajavelu also recently made the following trade(s):
- On Friday, November 7th, Esther Rajavelu sold 40,270 shares of Spero Therapeutics stock. The shares were sold at an average price of $2.37, for a total value of $95,439.90.
Spero Therapeutics Trading Up 3.0%
Shares of SPRO stock traded up $0.07 on Friday, hitting $2.37. 164,211 shares of the stock were exchanged, compared to its average volume of 290,629. The firm has a market capitalization of $133.53 million, a P/E ratio of -2.99 and a beta of 1.45. Spero Therapeutics, Inc. has a fifty-two week low of $0.51 and a fifty-two week high of $3.22. The business has a 50-day moving average of $2.35 and a 200 day moving average of $2.24.
Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last announced its earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.12. Spero Therapeutics had a negative return on equity of 125.91% and a negative net margin of 108.11%.The business had revenue of $5.44 million for the quarter, compared to analyst estimates of $12.00 million. As a group, research analysts forecast that Spero Therapeutics, Inc. will post -1.2 EPS for the current fiscal year.
Hedge Funds Weigh In On Spero Therapeutics
A number of institutional investors have recently bought and sold shares of the business. Invesco Ltd. bought a new stake in Spero Therapeutics in the second quarter valued at approximately $43,000. Dimensional Fund Advisors LP bought a new position in shares of Spero Therapeutics during the 3rd quarter worth approximately $55,000. Assenagon Asset Management S.A. acquired a new position in shares of Spero Therapeutics during the 3rd quarter worth approximately $70,000. Quadrature Capital Ltd bought a new stake in Spero Therapeutics in the 2nd quarter valued at $90,000. Finally, Two Sigma Investments LP acquired a new stake in Spero Therapeutics during the 3rd quarter valued at $93,000. Institutional investors and hedge funds own 25.60% of the company's stock.
Analyst Ratings Changes
SPRO has been the subject of a number of analyst reports. Zacks Research downgraded shares of Spero Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 13th. Wall Street Zen upgraded shares of Spero Therapeutics from a "hold" rating to a "buy" rating in a research note on Sunday, January 11th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Spero Therapeutics in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Reduce".
Check Out Our Latest Research Report on Spero Therapeutics
Spero Therapeutics Company Profile
(
Get Free Report)
Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.
The company's lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
